91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
(pages 16-17) features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
-
91黑料 talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter (pages 14 & 15) features a Q&A with EB McLindon, Senior VP, Site, Patient and Decentralised Solutions, on the inclusivity of decentralised clinical trials.
-
An article examining , featuring expert commentary from 91黑料's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
-
by Peter Schueler which considers the importance of patient engagement and enrollment in Alzheimer's clinical trials.
This article is taken from International Clinical Trials November 2020, pages 10-12. ? Samedan Ltd.
-
.jpg?w=545&itok=WjjDeARM "IPT discussed in technical publications.")
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2020, pages 38-40. ? Samedan Ltd
-
A by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
-
that 91黑料 continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
91黑料’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
91黑料’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile are temporarily halted as a result of potential safety issues being flagged by independent Data and Safety Monitoring Boards. Read more in this article.
.jpg?w=340&itok=_weN-aN8 "IPT discussed in technical publications."){kind=icon}
